Exanta “Not Approvable” Decision Leads To $80 mil. Charge
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca has taken an $80 mil. charge against half the assets associated with Exanta following FDA's "not approvable" decision
You may also be interested in...
AstraZeneca Refocuses On Risk Management, Elevates Development Oversight
Former Exec VP-Product Strategy & Licensing John Patterson will assume the board-level position of exec director-development effective Jan. 1. Regulatory affairs overhaul will include a review of ongoing Phase III programs for Galida, Cerovive and Symbicort.
AstraZeneca Refocuses On Risk Management, Elevates Development Oversight
Former Exec VP-Product Strategy & Licensing John Patterson will assume the board-level position of exec director-development effective Jan. 1. Regulatory affairs overhaul will include a review of ongoing Phase III programs for Galida, Cerovive and Symbicort.
AstraZeneca’s Exanta “Not Approvable” At FDA
Review decision comes two weeks ahead of the anticoagulant’s user fee date and follows CEO McKillop’s comments to investors that “we can’t be optimistic about the outcome of discussions with the FDA.”